Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Safety Study of TRUE AVC in Hemodialysis
NCT05567757Phase 2Completed
- Sponsor
- Vascudyne
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in chronic kidney disease (CKD), sponsored by Vascudyne. Primary endpoints: Adverse Event Incidence at 26 weeks and Patency at 26 weeks. Started Oct 2022; status: completed.
02
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05567757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05567757.